All In Biotech

Drug Trial Radar · NCT03387852

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-Severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy

Last checked: Nov 19, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

296

Actual

Start

Mar 12, 2018

Primary completion

Mar 21, 2019

Study completion Aug 7, 2019

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Jan 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events. Secondary Objectives: To evaluate the effects of SAR440340/REGN3500 and coadministration of SAR440340 and dupilumab, compared with placebo, on forced expiratory volume in 1 second (FEV1). To evaluate the effects of coadministration of SAR440340 and dupilumab, compared with SAR440340 and compared with dupilumab, on FEV1. To assess safety and tolerability of SAR440340 alone and in coadministration with dupilumab.

Conditions

  • Asthma

Interventions

  • SAR440340Drug

    Pharmaceutical form: Solution for Injection, Route of administration: SC

  • DupilumabDrug

    Pharmaceutical form: Solution for Injection, Route of administration: SC

  • Fluticasone or Fluticasone/salmeterol combinationDrug

    Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled

  • Placebo for SAR440340Drug

    Pharmaceutical form: Solution for Injection, Route of administration: SC

  • Placebo for dupilumabDrug

    Pharmaceutical form: Solution for Injection, Route of administration: SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Loss of Asthma ControlTime frame: From Baseline up to Week 12

Locations

71 sites in 8 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400026

    Birmingham, Alabama

  • Investigational Site Number 8400004

    Long Beach, California

  • Investigational Site Number 8400020

    Los Angeles, California

  • Investigational Site Number 8400001

    Rolling Hills Estates, California

  • Investigational Site Number 8400013

    San Jose, California

  • Investigational Site Number 8400009

    Stockton, California

  • Investigational Site Number 8400016

    Colorado Springs, Colorado

  • Investigational Site Number 8400021

    Ann Arbor, Michigan

  • Investigational Site Number 8400022

    Minneapolis, Minnesota

  • Investigational Site Number 8400007

    Papillion, Nebraska

  • Investigational Site Number 8400025

    Edmond, Oklahoma

  • Investigational Site Number 8400011

    Medford, Oregon

  • Investigational Site Number 8400024

    Portland, Oregon

  • Investigational Site Number 8400010

    Dallas, Texas

  • Investigational Site Number 8400023

    Dallas, Texas

  • Investigational Site Number 8400006

    Plano, Texas

  • Investigational Site Number 8400008

    Murray, Utah

  • Investigational Site Number 8400014

    Milwaukee, Wisconsin

  • Investigational Site Number 0320001

    Buenos Aires, Argentina

  • Investigational Site Number 0320003

    Caba, Argentina

  • Investigational Site Number 0320002

    Caba, Argentina

  • Investigational Site Number 0320004

    Caba, Argentina

  • Investigational Site Number 0320005

    Mendoza, Argentina

  • Investigational Site Number 1520002

    Quillota, Chile

  • Investigational Site Number 1520001

    Santiago, Chile

  • Investigational Site Number 1520009

    Santiago, Chile

  • Investigational Site Number 1520008

    Santiago, Chile

  • Investigational Site Number 1520007

    Santiago, Chile

  • Investigational Site Number 1520004

    Santiago, Chile

  • Investigational Site Number 1520005

    Talca, Chile

  • Investigational Site Number 1520003

    Viña del Mar, Chile

  • Investigational Site Number 4840005

    Chihuahua City, Mexico

  • Investigational Site Number 4840004

    Durango, Mexico

  • Investigational Site Number 4840002

    Guadalajara, Mexico

  • Investigational Site Number 4840006

    Monterrey, Mexico

  • Investigational Site Number 4840001

    Monterrey, Mexico

  • Investigational Site Number 4840003

    Veracruz, Mexico

  • Investigational Site Number 6160001

    Bialystok, Poland

  • Investigational Site Number 6160008

    Bialystok, Poland

  • Investigational Site Number 6160005

    Bydgoszcz, Poland

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.